Alliance Pharmaceutical of San Diego hopes to have its first imagingagent approved for the U.S. market by fall, according to Hal W.De Long, executive vice president of business development andmarketing. Imagent-GI is an oral gastrointestinal agent for
Alliance Pharmaceutical of San Diego hopes to have its first imagingagent approved for the U.S. market by fall, according to Hal W.De Long, executive vice president of business development andmarketing. Imagent-GI is an oral gastrointestinal agent for magneticresonance imaging that darkens the bowels and allows clearer imagingof abdominal organs.
Imagent-GI is Alliance's first application of its patented,perfluorocarbon contrast products based on a synthetic compoundcalled perfluorooctylbromide (PFOB). Other PFOB imaging productsinclude Imagent-BP, a blood-pool computed tomography and ultrasoundagent targeting metastatic liver cancer, and Imagent-LN, a lymphnode tumor agent for CT imaging (SCAN 2/28/90).
Alliance submitted an investigational new drug (IND) applicationin December for Imagent-BP, but has run into unexpected delaysat the Food and Drug Administration. The delays have been duein part to a high turnover of reviewers, De Long said.
"We are on our third (FDA) toxicologist," he noted."Every time there is a turnover (in staff), someone elsehas to brought up (to speed) on the file."
Alliance has licensed international rights to its PFOB imagingagents to Boehringer Ingelheim, a West German pharmaceutical company,and is seeking a distributor to handle U.S. sales, he said.
PFOB also has cardiovascular therapeutic applications relatedto it oxygen-carrying characteristics. Alliance is investigatinglicensing opportunities on the therapeutic side, De Long said.
The company hired Jack DeFranco as vice president of marketingin January. He will work with Imagent product managers to assistthe U.S. distributor.
"We made a decision not to do direct marketing, and arenow considering various distributor candidates," De Longsaid.
BRIEFLY NOTED:
Genesys of Maitland, FL, incorporates the IBM RS/6000 workstation(see story, page one) into its PACS and teleradiology equipment.Bio-Medical Imaging has formed a division to market the Genesysline under the brand name Provue.
Bio-Medical Imaging is an established regional medical imagingdistributor with a solid customer base, said Michael R. Kerouac,Genesys president. The distributor handles x-ray, mammographyand ultrasound equipment and will work with IBM to sell and servicethe PACS line, he said.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.